{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.1","value":"5.47"},{"groupId":"OG001","spread":"3.48","value":"5.84"}]}],"title":"Trastuzumab Deruxtecan"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7","value":"6.39"},{"groupId":"OG001","spread":"5.00","value":"7.16"}]}],"title":"Total Anti-HER2 Antibody"},{"categories":[{"measurements":[{"groupId":"OG000","spread":".0003","value":".0003"},{"groupId":"OG001","spread":".0002","value":".0003"}]}],"title":"DXd (Metabolite Active Metabolite MAAA-1181a)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK Analysis Set included all randomized subjects who received at least one dose of study drug and had any measurable post-dose serum concentrations of T-DXd, total anti-HER2 antibody, and DXd.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1; Cycle 2 Day 1, and Cycle 3 Day 1: pre- and post-dose; Cycle 1 Day 8: 7 days post-dose; Cycle 1 Day 15: 14 days post-dose; Cycle 4 Day 1 and Cycle 6 Day 1: pre-dose (each cycle is 21 days)","title":"Pharmacokinetic Parameter Minimum Observed Concentration (Ctrough) for Trastuzumab Deruxtecan, Total Anti-HER2 Antibody, and Active Metabolite MAAA-1181a","type":"SECONDARY","unitOfMeasure":"µg/mL"}